Trial Profile
A phase II trial of bevacizumab plus Gemcitabine and Oxaliplatin as first line therapy in metastatic or locally advanced (unresectable) pancreatic cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 08 Jul 2008 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 26 Nov 2005 New trial record.